RE:RE:Zack ReportIt's always great to be positive, promotional to keep up morale on the board...it's always also good to be realistic. Double digits is a long way from an acceptable single digit, like $5.00, which I would be pleased to see with a successful Phase III. Pfizer has been characterized as a law firm disguised as a BP. Last time I checked an acquiring business makes acquisitions, with shareholders money, with the idea of making a substantial profit. One must bear in mind that a successful Phase III encapsulates only a portion of the market, important as it may be. There are so many fledgling bio techs that have a much less checkered past than RVX. Therefore my point of a double digit gain in the stock price, as joyful as this would be, seems out of the question when looking at the Zack report. It will be instructive to see what rabbit DM pulls out of the hat by or on Sept 30, 2015. I will wait with bated breath.